On August 19, 2025, Proacta S.A. signed a cooperation agreement within the framework of the Polish Health Labs4Value Network (PSHL4V). The initiative involves leading medical and scientific institutions in Poland, including the Medical University of Łódź, the Łódź University of Technology, clinical hospitals in Łódź, Warsaw, and Kielce, as well as the Senior Activation System Foundation.

The agreement will enter into force on March 1, 2026, and has been concluded for an indefinite period.

The aim of the cooperation within PSHL4V is to:

• support innovation in healthcare,
• develop modern medical technologies and telemedicine,
• improve the quality of treatment and increase patient satisfaction,
• engage local communities in the process of creating innovation,
• support equality in access to healthcare,
• strengthen international scientific and implementation cooperation.

As a technology partner, Proacta will be responsible for developing and testing innovative solutions in so-called Living Labs, i.e., spaces used for the practical verification of new technologies in healthcare.

Joining the Polish Health Labs4Value Network opens up new opportunities for us to collaborate with the most important medical centers in the country. This is a huge opportunity for Proacta to develop innovation.wacyjnych rozwiązań i realny wpływ na poprawę jakości opieki zdrowotnej w Polsce i poza jej granicami.

We are pleased to announce that the latest materials are available on the investor relations website: Separate interim report for the second quarter of 2025 and results presentation.

Key conclusions:

• 134% increase in revenue y/y – to PLN 3.1 million.
• EBITDA exceeded PLN 1.6 million, and net profit amounted to nearly PLN 1.1 million – a clear rebound after losses in Q2 2024.

The basis for success:

• Commencement of two significant contracts:
  • Project with the Medical University of Warsaw for AI digital colposcopy (PLN 6.83 million, 98% of the value attributable to Proacta),
  • Dbam o Siebie Smart LAB platform (over PLN 5.6 million, co-financing of nearly PLN 4 million)

Transparency at a new level:

Starting with this report, the Company undertakes to publish its estimated financial results within 30 days after the end of the quarter, which constitutesi element strategii zwiększania transparentności działania

In a recent interview with PAP Biznes, Proacta representatives announced that by the end of 2025, the company will focus on implementing projects on the Polish market. This decision is related to the growing demand for innovative medical solutions in the country and the dynamic development of its own products, in particular the Dbam o siebie Smart LAB platform.

The interview touched upon, among other things, the development of the B2B model, cooperation with medical universities, and pilot projects with large medical networks. The company also pointed to a significant increase in revenue (116% y/y in Q2 2025) and stable foundations for further investments.

The full interview is available here PAP Biznes – read

In the program “Spółka pod lupą” (Company under the microscope) broadcast on BIZNES24, Vice President of the Management Board Maciej Grzywacki presented the current achievements of Proacta SA and announced ambitious development plans. The conversation focused on, among other things, impressive financial results, the company’s strategy in the bioinformatics sector, and future research and development projects.

116% increase in net revenue y/y

Proacta estimates that in the second quarter of 2025, it achieved PLN 2.6 million in net revenue, which represents a 116% increase year-on-year.

As Maciej Grzywacki emphasized:

“This was not a random jump. It is the result of a consistently implemented strategy that we have been working on for a year and a half.”

Strategy: AI, medicine, and bioinformatics

For over eight years, Proacta has been developing unique competencies combining technology and medicine.

The current strategy focuses on:

• creating and delivering analytical and predictive models for the medical sector
• developing its own IT products
• providing bioinformatics services to research centers and public institutions
• cooperating with universities and partners in R&D projects

Own solution: Smart LAB

The key product is the Dbam o Siebie Smart LAB platform, which enables the interpretation of blood test results.

As the Vice President pointed out:

“The platform is undergoing further development and forms the foundation of our B2B activities. We are currently implementing several pilot projects, which will soon show its real impact on the efficiency of the healthcare system.”

Plans for the future

The company is not slowing down.

“We have entered areas that are crisis-resistant. This is just the beginning,” summarized Maciej Grzywacki.

See the entire material and learn about the development directions of Proacta SA interview on our YouTube channel

In the interests of transparent communication and in accordance with corporate governance principles, the Management Board of Proacta S.A. has published answers to questions submitted by the Company’s shareholders. This document has been made available in accordance with principles 1.1 and 1.2 of the 2021 Code of Best Practice for WSE Listed Companies.

The most important issues addressed in the published responses include:

🔹 Assimilation of series N shares

🔹 Applications for co-financing of research and development projects

The full text of the responses is available in the Questions and Answers tab.